---
title: "Actuate Therapeutics, Inc. (ACTU.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ACTU.US.md"
symbol: "ACTU.US"
name: "Actuate Therapeutics, Inc."
industry: "生物技術"
---

# Actuate Therapeutics, Inc. (ACTU.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [actuatetherapeutics.com](https://actuatetherapeutics.com) |

## Company Profile

Actuate Therapeutics, Inc.是一家臨床階段的生物制藥公司，專注于開發用于治療美國癌症的療法。該公司的主要產品候選藥物是 elraglusib 注射液，這是一種糖原合酶激酶-3 抑制劑，目前正在進行第二階段臨床試驗，以治療轉移性胰腺導管腺癌。它還在開發 elraglusib，該藥物正在進行第一/第二階段臨床試驗，用于治療難治性兒童惡性腫瘤，包括尤文肉瘤，以及轉移性黑色素瘤和結直腸癌。該公司之前被稱為 Apotheca Therapeutics, Inc

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.60 | 328/606 | - | - | - |
| PB | 7.95 | 358/606 | 1436.01 | 15.24 | 11.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-15T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.74 |
| Highest Target | 35.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ACTU.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ACTU.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ACTU.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.